Insurance arrangements for direct-acting antivirals, where hepatitis C virus patients share the burden of treatment costs, are ineffective says one researcher.
A real-world study confirms the effectiveness and safety of the all-oral combination of sofosbuvir plus ribavirin for treatment of hepatitis C virus GT2 infection.
U.S. study finds those with HCV three times more likely to drink five or more drinks per day every day vs. those without HCV infections.
Removing potential barriers to treat hepatitis C virus is yet another key component to patient access, notes lead researcher.
HCVcAg tests may cost less and improve diagnostic capacity in settings of high hepatitis C virus prevalence, according to new research.
States had restricted Medicaid recipients’ access to drugs, but new court rulings are changing that practice.
Lead researcher says economic impact of hepatitis C virus will increase unless action is taken now.
Researchers find that direct-acting antivirals are better tolerated in patients with hepatitis C virus infections vs. interferon-based therapy.
PCPs can “play a decisive role in eradicating” hepatitis C virus in the U.S., says lead author of new study.
A new report finds that hepatitis B and C can be eliminated as a public health problem.